Clinical advantages of lipophilic dihydropyridines

Blood Pressure

Volumn 7, Issue SUPPL. 2, 1998, Pages 23-26

  Mancia, Giuseppe ^a   Omboni, Stefano ^a   Zanchetti, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

ambulatory blood pressure; clinic blood pressure; lercanidipine; lipophilicity; tachycardia

Indexed keywords

EID: 0032253198     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/080370598438447     Document Type: Article

References (30)

1. Lee CR, Bryson HM. Lacidipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs 1994; 48: 274-96.
2. Guarnieri L, Sironi G, Angelico P, et al. In vitro and in vivo selectivity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S25-32.
3. Mancia G. Ambulatory blood pressure monitoring: research and clinical applications. J Hypertens 1990; 8 (Suppl. 7): S1-13.
4. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring. Use in hypertension research and clinical practice. Hypertension 1993; 21: 510-24.
5. Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA 1983; 249: 2792-8.
6. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-36.
7. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study. N Engl J Med 1990; 322: 1561-6.
8. Mancia G, Zanchetti A, Agabiti-Rosei E, et al for the SAMPLE study Group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment - induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-70.
9. Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of trough-to-peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995; 13: 1105-12.
10. Mancia G, Salvetti A. Il rapporto valle/picco nella valutazione di un farmaco antiipertensivo [The trough-topeak ratio in the evaluation of an antihypertensive drug]. G Ital Cardiol 1994; 24: 1043-8.
11. Mancia G, Ferrari A, Gregorini L, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983; 53: 96-104.
12. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens 1987; 5: 93-8.
13. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11: 1133-7.
14. Parati G, Rizzoni D, Omboni S, Agabiti-Rosei E, Mancia G. "Smoothness index" but not T/P ratio estimates balanced 24 hour blood pressure control and predicts regression of organ damage by antihypertensive treatment. J Hypertens 1997; 15 (Suppl. 4): S7-8 (Abstract).
15. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994; 24: 287-96.
16. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454-7.
17. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2.
18. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997; 15: 3-17.
19. Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 1997; 14: 897-901.
20. Catapano AL. Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J 1997; 18 (Suppl. A): A80-6.
21. Brown MJ, Castaigne A, Ruilope LM, et al. INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. J Human Hypertens 1996; 10 (Suppl. 3): 157-60.
22. Loaldi A, Polese A, Montorsi P, et al. Comparison of nifedipine, propranolol and isorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol 1989; 64: 433-9.
23. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940-53.
24. Zanchetti A. Prevalence of carotid atherosclerosis in hypertension. Preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). Blood Press 1996; 5 (Suppl. 4): 30-5.
25. Paterna S, Licata S, Arnone C, Cottone C, Corrao S, Licata G. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50-3.
26. Rengo F, Romis L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S54-8.
27. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26-30.
28. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31-5.
29. Barbagallo Sangiorgi G, Putignano E, Calcara L, Barbagallo M. Efficacy and tolerability of lercanidipine vs. capropril in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S36-9.
30. Omboni S, Zanchetti A on behalf of the Multicentric Study Investigators. Antihypertensive efficacy of lercanidipine 2.5, 5 and 10 mg in mild to moderate essential hypertension assessed by clinic and ambulatory blood pressure measurements. J Hypertens: submitted.